TNF has a very powerful antitumor activity. Therapeutic administration of TNF to tumor-bearing animals or to human patients, however, is greatly limited by its toxicity, which is due to its strong proinflammatory nature. Indeed, injection of TNF leads to refractory hypotension, systemic inflammation, multi-organ failure, shock, and death, collectively known as systemic inflammatory response syndrome (SIRS) (1). Only a fundamental understanding of the mechanisms, molecules, and cells leading to TNF-induced SIRS will allow full exploitation of the potent antitumor activity of TNF in specific interventions against cancer. Our previous findings demonstrated that manipulation of several pathways protects the host against the toxicity of TNF without affecting its antitumor activity (2, 3).

IL-17 belongs to a family of proinflammatory cytokines (4). The role of IL-17 in host immune defense and in inflammation has been studied extensively in recent years. Numerous subtypes of IL-17—like ligands and IL-17R—like receptors have been described. The IL-17 family consists so far of six members, IL-17A to IL-17F. Their receptors, IL-17R and IL-17RB–E, form a family whose ligand specificity is only partially known (4). IL-17 is mainly produced by a subset of T cells implicated in autoimmune inflammation; these cells, designated Th17 cells, arise from a CD4 precursor pool and are distinct from Th1 or Th2 cells (5–7). Spontaneous development of Th17 causes autoimmune arthritis (8). IL-17–neutralizing antibodies or deletion of the IL-17 or IL-17R protects animals in models of autoimmune inflammation; these cells, designated Th17 cells, arise from a CD4 precursor pool and are distinct from Th1 or Th2 cells (5–7). Spontaneous development of Th17 causes autoimmune arthritis (8). IL-17–neutralizing antibodies or deletion of the IL-17 or IL-17R protects animals in models of autoimmune inflammation; these cells, designated Th17 cells, arise from a CD4 precursor pool and are distinct from Th1 or Th2 cells (5–7). Spontaneous development of Th17 causes autoimmune arthritis (8). IL-17–neutralizing antibodies or deletion of the IL-17 or IL-17R protects animals in models of autoimmune inflammation; these cells, designated Th17 cells, arise from a CD4 precursor pool and are distinct from Th1 or Th2 cells (5–7). Spontaneous development of Th17 causes autoimmune arthritis (8). IL-17–neutralizing antibodies or deletion of the IL-17 or IL-17R protects animals in models of autoimmune inflammation; these cells, designated Th17 cells, arise from a CD4 precursor pool and are distinct from Th1 or Th2 cells (5–7).
in a model of TNF-induced lethal shock. We demonstrate
that inhibition of IL-17 or IL-17R strongly protects against
TNF-induced gene induction, organ damage, and death. Furthermore,
we found that intestinal Paneth cells produce and re-
lease a high level of IL-17 during inflammation.

RESULTS AND DISCUSSION
Neutralizing antibodies against IL-17 protect mice against
a lethal TNF challenge
We investigated the role of IL-17 in TNF-induced shock us-
ing neutralizing antibodies. Mice were injected i.v. with 10 μg
TNF 2 h after treatment with 100 μl of a rabbit anti–IL-17
antiserum. Control mice received an equal volume of rabbit
preimmune serum. Mortality was monitored for up to 60 h,
and body temperature was assessed 4 and 6 h after injection.
In the first experiment, all five control mice died within 24 h
after challenge, whereas all three mice treated with anti–IL-17
antiserum survived. Mice pretreated with anti–IL-17 were
significantly protected against hypothermia (not depicted). In
the second experiment, significant protection by the anti–IL-17
serum was again observed (Fig. 1 A). This antiserum specifi-
cally neutralized IL-17(A) but not IL-17F, as shown by an in
vitro assay (Fig. 1 B). As IL-17 is produced mainly by a subset
of T cells, its role is presumably restricted to infl ammation as-
sociated with underlying T cell–mediated immunity, such as
autoimmunity or allergy (6, 9, 10, 12, 15). The time course
of IL-17 production is slow, refl ector the development of
a specific T cell subset (6). However, in our model, SIRS

Figure 1. Anti–IL-17 antibody protects mice against TNF-induced
lethal shock. (A) Mice were pretreated 2 h before TNF challenge with 100 μl
anti–IL-17 serum (n = 7), 100 μl control rabbit serum (n = 6), or PBS (n = 7).
Mortality was monitored for 60 h after challenge. No further deaths oc-
curred. **, P = 0.0074, preimmune versus anti–IL-17 serum; ***, P = 0.0072,
PBS versus anti–IL-17 serum. (B) H4 cells were incubated with 25 ng/ml
IL-17(A) or 25 ng/ml IL-17F with or without anti–IL-17 serum (1:400).
**, P = 0.0044; ***, P = 0.0001.

Figure 2. IL-17R KO mice are less susceptible to TNF-induced shock.
TNF was injected i.v. in WT (n = 7) and IL-17R KO (n = 7) mice, and mortality
was monitored. Blood samples were taken 3 h after the injection, and serum samples were tested for IL-6 and NOx. (A and B) Survival curves after 10
and 7.5 μg TNF, respectively. *, P = 0.00175 and **, P = 0.0075 compared with WT control. (C and D) Serum levels of NOx (***, P = 0.0002; n = 5) and IL-6 (**,
P = 0.0017; n = 6) 3 h after injecting 7.5 μg TNF.
between IL-17 and other proinflammatory cytokines such as TNF and IL-1 (14, 15).

Reduced serum levels of IL-6 and nitric oxide (NO) metabolites and reduced tissue damage and inflammation in IL-17R KO mice

Serum levels of IL-6 and NO metabolites increase after injection of TNF, faithfully reflect the degree of TNF-induced shock, and correlate with lethality (3, 18). 3 h after injection of 7.5 μg TNF, NOx levels increased to 120 μM in WT mice but remained significantly lower in IL-17R KO mice (Fig. 2 C). Similarly, the increase in serum IL-6 concentration was large in WT mice but significantly less in IL-17R KO mice (Fig. 2 D). These results strongly support the mediating role of IL-17, together with its receptor, in TNF-induced shock.

TNF injected into mice or humans causes severe inflammation and tissue damage in the small bowel (19). 3 h after injection of 7.5 μg TNF, small bowel samples (jejunum) were collected and stained for histopathological and immunohistochemical (IHC) analyses. The intestinal epithelium of TNF-treated WT mice (n = 6) was extensively damaged, with partial loss of morphological structure. The villi were flattened...
and their tops were denuded or missing. Crypts contained mucus and debris (Fig. 3 A). In contrast, the morphology of all IL-17R KO intestines (n = 6) after TNF challenge was almost normal with little or no damage (Fig. 3 B). Staining the intestinal sections of WT mice for leukocytes with an anti-CD45 antibody 3 h after TNF injection demonstrated massive leukocyte influx in the villi, where the extensive tissue damage occurred (Fig. 3 C). Much fewer leukocytes were found in the IL-17R KO mice, correlating with the absence of tissue damage (Fig. 3 D and E). IL-17 induces expression of CXC chemokines, such as CXCL1, which account for chemotaxis of leukocytes (14) and activates neutrophils to release elastase and myeloperoxidase (MPO) in vivo (20). In line with this, by using anti-MPO antibody we observed neutrophil infiltrate in some WT mice, which was not seen in any of the IL-17R KO mice (not depicted).

Induction of IL-17 by TNF
Protection against TNF-induced shock by the anti–IL-17 antibody and by genetic deletion of the IL-17R indicates that IL-17 is produced endogenously and acts synergistically to enhance the actions of TNF. To test this hypothesis, we studied the time course of IL-17 abundance in the serum and small intestine where the pronounced tissue damage was observed after TNF administration. Serum samples were screened for IL-17 activity by Luminex assay; IL-17 remained below the detection limit (10 pg/ml) at all time points (not depicted). However, IHC examination using an antibody against mouse IL-17 revealed IL-17+ cells in the small intestine. Jejunum of untreated mice showed a constitutive level of IL-17 in cells located at the crypt bottom, which is surprising (Fig. 4 A). A few faint signals could occasionally be found in lamina propria, but the most prominent specific signal was found at the crypt bottom. The IL-17 signal clearly increased 1 h after TNF administration, peaked at 3 h, and remained high up to 9 h (not depicted). At 3 h after TNF administration, the overall signal intensity was dramatically increased and extended outward to the surface of the villi (Fig. 4 B). That the antibody is IL-17 specific was confirmed using the tissue of untreated IL-17 KO mice (provided by Y. Iwakura, Tokyo University, Tokyo, Japan) (Fig. 4 C). As lamina propria lymphocytes and γδT cells are the dominant cell types producing IL-17 (20–22), the increased IL-17 associated with the villi can be partly attributed to these cells. The negative control for each time point was devoid of any signal (Fig. 4, D and E, respectively). This local expression was characteristic of IL-17, as we did not detect any signal using antibody against IL-1β or IL-18 (not depicted). As the unexpected localization of IL-17 at the crypt bottom seemed to be associated with Paneth cells on morphological grounds, we further explored the identity of these cells using the IL-17 antibody and a specific anti-matrilysin antibody on serial sections (Fig. 4, H and I). Because γδT cells reside in the intraepithelial layer (23) and not at the crypt bottom (24), it is unlikely that the observed signal

Figure 4. Expression of IL-17 in mouse jejunum after TNF injection. Small intestines were dissected from untreated mice (A, C, D, F, H, and I) and 3 h after i.v. injection with 7.5 μg TNF (B and E). WT mice (A, B, D, E, H, and I), matrilysin-deficient mice (F), and IL-17-deficient mice (C) were used. (A, B, C and H) IHC with anti–IL-17 antibody shows presence of IL-17 by TNF in Paneth cells at 0 h (A and H) and 3 h (B). No signal could be detected in IL-17-deficient mice (C). (D and E) Negative control with control antibody at 0 h (D) and 3 h (E). (F and I) IHC with anti-matrilysin antibody shows expression of matrilysin in Paneth cells of WT mice (I) and its absence in matrilysin KO mice (F). (G) Real-time PCR for IL-17 in samples isolated from jejunum at indicated times. *, P = 0.0458. Bar, 50 μm.
came from this cell type. The matrilysin signal was specific, as shown by the absence of signal in matrilysin-deficient mice (Fig. 4 F). Matrilysin has been shown to be specifically expressed in Paneth cells, where it activates α-defensins (25). We confirmed the expression of IL-17 in the jejunum by real-time PCR; 3 h after TNF challenge, the transcript level of IL-17 was significantly up-regulated, about threefold (Fig. 4 G).

**Identification of Paneth cells as the producers of IL-17**

Co-localization of IL-17 and matrilysin strongly indicated that Paneth cells are the likely producers of IL-17, and so we set out to confirm this by electron microscopy (EM). We examined the localization of IL-17 within Paneth cells by using immunogold (Fig. 5 A). The Paneth cells were identified on the basis of typical ultrastructural morphology with large secretory granules and abundant endoplasmic reticulum. The gold particles were closely associated with secretory granules (Fig. 5 A, black arrow), demonstrating high constitutive levels of IL-17 in Paneth cells. Some signals were associated with microvilli (Fig. 5 A, white arrow), most likely due to secreted IL-17 adhering on the surface. We did not detect any γδT cells producing IL-17 because the sensitivity might have been too low or because their spatial distribution might have made it difficult to identify these cells in the ultrathin sections. Contrary to expectation, the level of IL-17 within the Paneth cells declined 3 h after injection with TNF (Fig. 5 B). The negative control using the control antibody was devoid of any signal, confirming the specificity of the observed signal (Fig. 5 C). This finding seemed to contradict the result of IHC using the same antibody, where an increase in the signal was detected after TNF injection. This seeming discrepancy might be due to TNF inducing rapid secretion of IL-17 stored in the granules. IHC may detect the cumulative level of secreted IL-17 around the neighboring cells beyond the immediately adjacent microvilli, whereas EM may not. Indeed, in IHC the strong signal was observed in the villi surface and occasionally in cells, presumably lamina propria lymphocytes and intraepithelial lymphocytes (Fig. 4 B).

**Figure 5. Expression of IL-17 in Paneth cells.** Small intestines were dissected from untreated mice (A and C) and 3 h after i.v. injection with 10 μg TNF (B) and examined by EM. Immunogold detection of IL-17 in secretory granules (black arrow) and in microvilli (white arrow) (A and B). Control antibody shows no signal (C). The antibodies used were the same as in Fig. 4. Bar, 1 μm.

Indeed, Paneth cells are very important in innate immunity against pathogens, expressing pattern recognition receptors, e.g., NOD2, and many antimicrobial peptides, such as lysozyme, soluble phospholipases, α-defensins, and cryptdin-related peptides (26). Paneth cells are involved in anti-parasitic immunity and also express several inflammatory molecules,
such as TNF, GM-CSF, and inducible NO synthase (27, 28). Moreover, Paneth cells have a clear capacity to respond to inflammatory cytokines as shown in the induction of inducible NO synthase by TNF (28). The leukocyte-like Paneth cells, because they release TNF, are thought to be essential both in mucosal immunity against pathogens and in development of Crohn’s disease. IL-17 expression seems to be increased in the colons of Crohn’s patients (29), but it has never been associated with Paneth cells until now.

To date, IL-17–producing cells were identified only among leukocytes: Th17 cells, subset of CD8+ cells, NK cells, αβT cells, γδT cells, and neutrophils (30). Our data clearly demonstrate that IL-17 is produced in Paneth cells and released upon challenge with TNF, and that it seems to be involved in a positive amplification loop together with the major IL-17 receptor. This receptor is expressed on a variety of cell types, such as fibroblasts, epithelial cells, endothelial cells, and leukocytes (4). Thus, Paneth cells clearly respond to TNF by producing IL-17 and this leads to a fast, mucosa-specific reaction. Th17 cells and γδT cells also participate in these mucosa-specific immune responses (23). For instance, Th17 cells play a role in mucosal innate immunity by inducing antimicrobial peptides (31). Th17 cells, γδT cells, and Paneth cells might participate in a coordinated interplay between innate and adaptive immunity in a spatiotemporally regulated manner to ensure the host defense at the local mucosa. This is in agreement with the role of local mucosal tissue as the first immunological barrier to pathogens. A rapid local amplification mechanism needed for defense, however, may turn out detrimental in case of systemic inflammatory syndromes caused by bacterial endotoxins or by TNF.

Our findings shed light on the role of Paneth cells as a ready source of IL-17, which amplifies signals in acute inflammation. It may also add a new dimension to the mechanism by which Paneth cells ensure mucosal immunity to gut pathogens.

MATERIALS AND METHODS

Mice. C57BL/6J WT mice were purchased from Iffa Credo. IL-17R KO mice (IL-17R KO) (16) and Matrilysin-deficient mice were provided by J.J. Peschon (Amgen Washington, Seattle, WA) and L. Matrisian (Vanderbilt University, Nashville, TN), respectively. Mouse lines had been crossed back into a C57BL/6J background for over five generations. The mice were kept in specific pathogen-free conditions and used at matched ages. Animal studies were approved by the Institutional Review Board of the Radboud University. Polyclonal rabbit antibodies were raised against recombinant murine IL-17A and anti–matrilysin antibody. Professor Yoichiro Iwakura of the Center for Experimental Medicine at the Institute for Medical Science of Tokyo University is acknowledged for providing recombinant murine IL-17A and anti–IL-17 serum. Dr. B. Fingleton (Vanderbilt University, Nashville, TN) provided matrilysin-deficient mice, and Dr. M. Boots (Organon N.V., Oss, Netherlands) for providing recombinant murine IL-17A and anti–IL-17 serum. Dr. B. Fingleton (Vanderbilt University, Nashville, TN) is acknowledged for providing the anti-matrilysin antibody. Professor Yoichiro Iwakura of the Center for Experimental Medicine at the Institute for Medical Science of Tokyo University is acknowledged for providing an IL-17 KO intestine and Dr. M. Netea is thanked for his help in this matter. We also wish to thank Ms. B. Walgreen and Ms. I. van den Brink for excellent technical assistance.

Statistical analysis. Student’s t test was used for statistical analysis. All p-values of <0.05 were considered significant.

We thank Dr. J.J. Peschon (Amgen Washington, Seattle, WA) for generously providing IL-17R KO mice, Dr. L. Matrisian (Vanderbilt University, Nashville, TN) for matrilysin-deficient mice, and Dr. M. Boots (Organon N.V., Oss, Netherlands) for providing recombinant murine IL-17A and anti–IL-17 serum. This work was supported by IOP Genomics (I6002032), by FWO Vlaanderen, Belgium, and the Interuniversity Attraction Pole, Belgium. I. Vanlaere is an aspirant of the FWO-Vlaanderen, Belgium. E. Lubberts was supported by a Veni Fellowship (grant no. 906-02-038) from the Netherlands Organization for Scientific Research (NWO). A. Cauwels is a postdoctoral fellow of the FWO-Vlaanderen, Belgium.

The authors have no other conflicting financial interests.
REFERENCES


